ArticlePLoS neglected tropical diseases2019
Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Cost-effectiveness of chikungunya vaccination with the live attenuated vaccine in U.S. territories.NPJ vaccines · 2025Article
- Estimating per-infection cost and burden for dengue and Zika as a function of antibody-dependent enhancement.PLoS neglected tropical diseases · 2025Article
- Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation.The American journal of tropical medicine and hygiene · 2023Article
- Human IgG responses to the Aedes albopictus 34k2 salivary protein: analyses in Réunion Island and Bolivia confirm its suitability as marker of host exposure to the tiger mosquito.Parasites & vectors · 2022Article
- Risk factors for infection with chikungunya and Zika viruses in southern Puerto Rico: A community-based cross-sectional seroprevalence survey.PLoS neglected tropical diseases · 2022Article
- Pandemic-associated mobility restrictions could cause increases in dengue virus transmission.PLoS neglected tropical diseases · 2021Article
- Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.PLoS neglected tropical diseases · 2021Article
- Cost-effectiveness of dengue vaccination in Puerto Rico.PLoS neglected tropical diseases · 2021Article
- Target product profile for a dengue pre-vaccination screening test.PLoS neglected tropical diseases · 2021Article
- Correlation between reported dengue illness history and seropositivity in rural Thailand.PLoS neglected tropical diseases · 2021Article
- Accuracy and efficacy of pre-dengue vaccination screening for previous dengue infection with five commercially available immunoassays: a retrospective analysis of phase 3 efficacy trials.The Lancet. Infectious diseases · 2021Article
- The economic burden of dengue fever in the Kingdom of Saudi Arabia.PLoS neglected tropical diseases · 2020Article
- IgG Antibody Responses to theFrontiers in cellular and infection microbiology · 2020Article
- On the Use of Markov Models in Pharmacoeconomics: Pros and Cons and Implications for Policy Makers.Frontiers in public health · 2020Article
- Hidden heterogeneity and its influence on dengue vaccination impact.Infectious Disease Modelling · 2020Article
- Analysis in a murine model points to IgG responses against the 34k2 salivary proteins from Aedes albopictus and Aedes aegypti as novel promising candidate markers of host exposure to Aedes mosquitoes.PLoS neglected tropical diseases · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 3 countries.
Funding
Abstract
The tetravalent dengue vaccine CYD-TDV (Dengvaxia) is the first licensed vaccine against dengue, but recent findings indicate an elevated risk of severe disease among vaccinees without prior dengue virus (DENV) exposure. The World Health Organization currently recommends CYD-TDV only for individuals with serological confirmation of past DENV exposure. Our objective was to evaluate the potential health impact and cost-effectiveness of vaccination following serological screening. To do so, we used an agent-based model to simulate DENV transmission with and without vaccination over a 10-year timeframe. Across a range of values for the proportion of vaccinees with prior DENV exposure, we projected the proportion of symptomatic and hospitalized cases averted as a function of the sensitivity and specificity of serological screening. Scenarios about the cost-effectiveness of screening and vaccination were chosen to be representative of Brazil and the Philippines. We found that public health impact depended primarily on sensitivity in high-transmission settings and on specificity in low-transmission settings. Cost-effectiveness could be achievable from the perspective of a public payer provided that sensitivity and the value of a disability-adjusted life-year were both high, but only in high-transmission settings. Requirements for reducing relative risk and achieving cost-effectiveness from an individual perspective were more restricted, due to the fact that those who test negative pay for screening but receive no benefit. Our results predict that cost-effectiveness could be achieved only in high-transmission areas of dengue-endemic countries with a relatively high per capita GDP, such as Panamá (13,680 USD), Brazil (8,649 USD), México (8,201 USD), or Thailand (5,807 USD). In conclusion, vaccination with CYD-TDV following serological screening could have a positive impact in some high-transmission settings, provided that screening is highly specific (to minimize individual harm), at least moderately sensitive (to maximize population benefit), and sufficiently inexpensive (depending on the setting).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.